Biotronik said today it won FDA approval for its MultiPole Pacing technology designed for its cardiac resynchronization therapy defibrillator systems.
The MPP technology is designed to treat the 40% of heart failure patients who are initially non-responsive to CRT by enabling the left ventricle to be paced twice per cardiac cycle, the Berlin, Germany-based company said.
“MultiPole Pacing is an important technology that allows physicians to tailor cardiac resynchronization therapy to each patient. Heart failure is a complex condition and physicians are routinely challenged to find the ideal treatment for unique disease presentations. Adding MPP technology to other key Biotronik features creates more options for physicians to meet evolving patient needs,” Dr. Gery Tomassoni of Lexington, Ky.’s Baptist Health said in a prepared statement.
Biotronik said that the altered pacing can be either sequential or simultaneous to allow for greater customization for specific patient needs.
“When we develop technologies and evolve our devices, we think first and foremost about patients. Patients deserve the best care possible and innovation that truly enhances everyday life. Patients with heart failure are the most complex to treat, and they often have additional comorbidities that are likely to change and worsen over time. Biotronik rises to this challenge by continuing to innovate, and offering impactful, customizable solutions to physicians that meet the ever-changing landscape of patients’ needs,” Biotronik prez Marlou Janssen said in a press release.
Last month, Biotronik launched its Plexa ProMRI 7.8 French MR conditional tachycardia lead in the US, touting it as the smallest lead of it’s kind on the market. The company said it won FDA approval for the leads in February 1, indicated for use with implantable cardioverter defibrillators and heart failure devices.
